What Editas Medicine Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 5 | 14 |
| Total trades | 5 | 14 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 11,892 | 41,861 |
| Net activity | −11,892 | −41,861 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Parison Amy | SVP, Chief Financial Officer | Sep 03 | Open-market sale · S | −453 | $3.04 | −$1.38K | 13,839 |
| O'Neill Gilmore Neil | CEO | Sep 03 | Open-market sale · S | −5,124 | $3.04 | −$15.6K | 243,189 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Sep 03 | Open-market sale · S | −709 | $3.04 | −$2.15K | 61,660 |
| Parison Amy | SVP, Chief Financial Officer | Aug 03 | Open-market sale · S | −678 | $2.58 | −$1.75K | 14,292 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Jul 28 | Open-market sale · S | −4,928 | $2.67 | −$13.2K | 62,369 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Jun 03 | Open-market sale · S | −731 | $2.70 | −$1.97K | 67,297 |
| O'Neill Gilmore Neil | CEO | Jun 03 | Open-market sale · S | −15,380 | $2.70 | −$41.5K | 248,313 |
| Parison Amy | SVP, Chief Financial Officer | Jun 03 | Open-market sale · S | −464 | $2.70 | −$1.25K | 14,970 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Mar 03 | Open-market sale · S | −749 | $2.02 | −$1.51K | 68,028 |
| O'Neill Gilmore Neil | CEO | Mar 03 | Open-market sale · S | −5,394 | $2.02 | −$10.9K | 263,693 |
| Parison Amy | SVP, Chief Financial Officer | Mar 03 | Open-market sale · S | −474 | $2.02 | −$957 | 15,434 |
| O'Neill Gilmore Neil | CEO | Dec 03 | Open-market sale · S | −5,603 | $2.15 | −$12.1K | 269,087 |
| Parison Amy | SVP, Chief Financial Officer | Dec 03 | Open-market sale · S | −461 | $2.15 | −$993 | 15,908 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Dec 03 | Open-market sale · S | −713 | $2.15 | −$1.54K | 68,777 |
| Parison Amy | SVP, Chief Financial Officer | Sep 03 | Open-market sale · S | −458 | $2.60 | −$1.19K | 16,369 |
| O'Neill Gilmore Neil | CEO | Sep 03 | Open-market sale · S | −5,592 | $2.60 | −$14.5K | 274,690 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Sep 03 | Open-market sale · S | −710 | $2.60 | −$1.84K | 69,490 |
| Parison Amy | SVP, Chief Financial Officer | Aug 07 | Open-market sale · S | −679 | $2.58 | −$1.75K | 16,827 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Jul 31 | Open-market sale · S | −5,121 | $2.49 | −$12.8K | 64,398 |
| O'Neill Gilmore Neil | CEO | Jun 03 | Open-market sale · S | −15,192 | $1.72 | −$26.2K | 280,282 |
Loading...